Products for Clotting Factor Replacement in Developing Countries

ABSTRACT

Developing countries provide clotting factor replacement for hemophilia patients using one or more of the following strategies. (1) Production of domestic plasma and cryoprecipitate provides some self-sufficiency but depends heavily on the presence of an excellent blood transfusion service. The risk of transmitting donor infections is not completely obviated even with good serologic testing. (2) Domestic plasma fractionation has been achieved in a handful of emerging countries but can be expensive. Patients may distrust businessmen of their own country and may be dissatisfied with the style of product available from domestic plants. (3) Contract fractionation has been successful when the donor country is able to provide adequate amounts of well-tested plasma. Its cost is not always lower than that of imported concentrate but a degree of national self-sufficiency is retained. (4) Importation of concentrate allows a wide choice of products. The selection should focus not only on price but also on product safety, which depends upon well-validated donor testing and viral inactivation. High levels of purification are not of great importance. Successful national hemophilia programs also address organization of care, sensible dosing, and equitable distribution of resources to gain the maximum benefit from scarce resources.

KEYWORDS

Developing countries - hemophilia - cryoprecipitate - factor VIII - plasma

REFERENCES

• 1 International Blood/Plasma News . 2003;  20 122
• 2 Srivastava A, Chuansumrit A, Chandy M, Duraiswamy G, Karabus C. Management of haemophilia in the developing world.  Haemophilia. 1998;  4 474-480
• 3 Antunes S V. Haemophilia in the developing world: The Brazilian experience.  Haemophilia. 2002;  8 199-204
• 4 Chandy M. Ethics of haemophilia care in the developing world.  Haemophilia. 2002;  8 439-440
• 5 Linney D R, Lazerson J. Hemophilia: cost consideration for prescribing therapeutic materials.  Transfusion. 1979;  19 57-59
• 6 Shan H, Wang J-X, Ren F-R et al.. Blood banking in China.  Lancet. 2002;  360 1770-1775
• 7 Goodnough L T, Shander A, Brecher M E. Transfusion medicine: looking to the future.  Lancet. 2003;  361 161-169
• 8 Moore A, Herrera G, Nyamongo J et al.. Estimated risk of HIV transmission by blood transfusion in Kenya.  Lancet. 2001;  358 657-660
• 9 Rogoff E G, Guirguis H S, Lipton R A et al.. The upward spiral of drug costs: a time series analysis of drugs used in the treatment of hemophilia.  Thromb Haemost. 2002;  88 545-553
• 10 Evatt B L, Austin H, Leon G, Ruiz-Saez A, De Bosch N. Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate.  Haemophilia. 1999;  5 295-300
• 11 Horowitz B, Bonomo R, Prince A M, Chin S N, Brotman B, Shulman R W. Solvent/detergent-treated plasma: A virus-inactivated substitute for fresh frozen plasma.  Blood. 1992;  79 826-831
• 12 Pamphilon D. Viral inactivation of fresh frozen plasma.  Br J Haematol. 2000;  109 680-693
• 13 Korneyeva M, Hotta J, Lebing W, Rosenthal R S, Franks L, Petteway Jr S R. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates.  Biologicals. 2002;  30 153-162
• 14 Owens W J, Shanbrom E. ‘Super-cryoprecipitate’: a new, safer method of producing plasma-derived factor VIII.  Vox Sang. 2002;  83(suppl 2) 137 , (abstract 407)
• 15 Grieb T, Forng R-Y, Brown R et al.. Effective use of gamma irradiation for pathogen inactivation of monoclonal antibody preparations.  Biologicals. 2002;  30 207-216
• 16 Hornsey V S, Krailadsiri P, MacDonald S, Seghatchian J, Williamson L M, Prowse C V. Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus-inactivated plasma.  Br J Haematol. 2000;  109 665-670
• 17 Bird A, Isarankura P, Almagro D, Gonzaga A, Srivastava A. Factor concentrates for haemophilia in the developing world.  Haemophilia. 1998;  4 481-485
• 18 Beal R. Transfusion science and practice in developing countries: ‘a high frequency of empty shelves'.  Transfusion. 1993;  33 330-332
• 19 Knevelman A, de Wit H JC, Postra P, van de Does J A. Development and small-scale production of a severely heat treated factor VIII concentrate.  Vox Sang. 1994;  66 89-95
• 20 Flesland O, Seghatchian J, Solheim B G. The Norwegian plasma fractionation project-a 12 year clinical and economic success story.  Transfus Apheresis Sci. 2003;  28 93-100
• 21 Farrugia A. Guide for the Assessment of Clotting Factor Concentrates for the Treatment of Hemophilia. World Federation of Hemophilia 2003
• 22 Wadhwa M, Dilger P, Tubbs J, Mire-Sluis A, Barrowcliffe T, Thorpe R. Identification of transforming growth factor -beta as a contaminant in factor VIII concentrates: a possible link with immunosuppressive effects in hemophiliacs.  Blood. 1994;  84 2021-2030
• 23 Berntorp E. Why prescribe highly purified factor VIII and factor IX concentrates?.  Vox Sang. 1996;  70 61-68
• 24 Gellert G A. Hemophilia replacement therapy in developing countries: complementary approaches to the question of indigenous product manufacture versus importation.  Thromb Haemost. 1996;  75 373-374
• 25 Chandy M. Ethics of haemophilia care in the developing world.  Haemophilia. 2002;  8 439-440
• 26 Evatt B L, Robillard L. Establishing haemophilia care in developing countries: using data to overcome the barrier of pessimism.  Haemophilia. 2000;  6 131-134
• 27 Evatt B L. Observations from Global Survey 2001: an emerging database for progress.  Haemophilia. 2002;  8 153-156
• 28 Isarangkura P. Haemophilia care in the developing world: benchmarking for excellence.  Haemophilia. 2002;  8 205-210
• 29 Hoots W K. The future of plasma-derived clotting factor concentrates.  Haemophilia. 2001;  7(suppl 1) 4-9
• 30 Mannucci P M. Treatment of hemophilia; recombinant factors only? No.  J Thromb Haemost. 2003;  1 216-217
• 31 Ali A M, Gandy R H, Britten M I, Dormandy K M. Joint haemorhage in haemophilia: Is full advantage taken of plasma therapy?.  BMJ. 1967;  3 828-831
• 32 Aronstam A, Wassef M, Choudhury D P, Turk P M, McLellan D S. Double-blind controlled trial of three dosage regimens in treatment of haemarthroses in haemophilia A.  Lancet. 1980;  1 169-171
• 33 Aronstam A, Wassef M, Hamad Z, Cartlidge J, McLellan D. A double-blind controlled trial of two dose levels of factor VIII in the treatment of high risk haemoarthroses in haemophilia A.  Clin Lab Haemotol. 1983;  5 157-163
• 34 Penner J A, Kelly P E. Lower doses of factor VIII for hemophilia.  N Engl J Med. 1977;  297 401
• 35 Kasper C K. An elective orthopaedic surgical repair: a reminiscence.  Haemophilia. 1996;  2 120-121
• 36 Kasper C K, Boylen A L, Ewing N PO, Luck Jr J V. Hematologic management of hemophilia A for surgery.  JAMA. 1985;  253 1279-1283
• 37 Srivastava A, Chandy M, Sunderaj G D et al.. Low-dose intermittent factor replacement for post-operative care in haemophilia.  Haemophilia. 1998;  4 799-801